Stem Cell Innovations Announces Issuance of Fundamental Human Stem Cell Patent
News Jan 10, 2007
Stem Cell Innovations, Inc. has announced the issuance of key patent covering human pluripotent stem cells in the United States.
“The patent provides a broad blocking position for the pluripotent cells of interest to Stem Cell Innovations as it covers isolated human primordial germ cell derived pluripotent cells,” said Stem Cell Innovations CEO Dr. James Kelly.
“We believe that this is a fundamental patent in human stem cell biology and an important addition to our foundational IP.” The patent was issued in the United States as U.S. Patent No. 7,153,684 and is licensed exclusively to Stem Cell Innovations.
Stem Cell Innovations is developing PluriCells™, a new human stem cell technology derived from primordial germ cells of fetal tissue. PluriCells are distinct from ES cells and are believed to be outside the competitive patents on human ES cells.
The spatial and temporal dynamics of proteins or organelles plays a crucial role in controlling various cellular processes and in development of diseases. However, acute control of activity at distinct locations within a cell cannot be achieved. A new chemo-optogenetic method enables tunable, reversible, and rapid control of activity at multiple subcellular compartments within a living cell.